Objective — to estimate the number of cases of occult uterine malignancies detected during all laparoscopic supracervical hysterectomy (LASH) operations at the Clinic for Minimally Invasive Surgery (Berlin) and to clarify how the surgical technique affects the prognosis of the disease. Subject and methods. The data of 10,731 patients who underwent a LASH surgery with electric power morcellation in the period 1998 to April 30, 2014 were retrospectively analyzed. The main indication for LASH was symptomatic uterine myoma (81.3%). Results. No intraoperative complication was caused by the use of a morcellator. In total, there were 6 (0.06%) patients with uterine sarcoma, including 4 (0.04%) with endometrial stromal sarcoma and 2 (0.02%) with leiomyosarcoma, and 8 (0.07%) patients with endometrial cancer. These findings suggest that there is a very low uterine malignancy rate (0.13%) found in patients diagnosed with symptomatic uteri morcellated during endoscopic intervention. The median follow-up period for all the 6 patients with uterine sarcoma and 7 patients with endometrial cancer was 65.58 (13—169) months. Throughout this period, there were no recurrences in the patients with endometrial cancer and in 5 women operated on for sarcoma. One patient died from leiomyosarcoma concurrent with peritoneal carcinomatosis and bone metastases 13 months after LASH. Conclusion. Sarcoma (0.06%) and endometrial carcinoma (0.07%) were detected among 10,731 morcellated uteri during LASH for symptomatic uterine sarcoma. All patients should be informed about that a malignant disease can be rarely identified during preoperative counseling. With a timely follow-up surgery according to the oncologic guidelines, our data suggest a very good prognosis in terms of survival after LASH with morcellation of malignant tumors in the uterus. The authors declare no conflicts of interest.